BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, January 18, 2026
Home » Topics » Neurology/psychiatric, BioWorld MedTech

Neurology/psychiatric, BioWorld MedTech
Neurology/psychiatric, BioWorld MedTech RSS Feed RSS

Braintale software

Braintale gains CE mark approval for its first quantitative brain measurement device

April 27, 2020
By Bernard Banga
PARIS – Braintale SAS, of Paris, has gained CE mark approval for Brainquant. This software platform, which uses DICOM radiology imaging, enables diffusion MRI scans to be processed as part of managing patients in a coma following brain injury.
Read More

BioWorld MedTech’s Neurology Extra for April 24, 2020

April 24, 2020
By Andrea Applegate and Anette Breindl
Keeping you up to date on recent developments in neurology, including: Nanocarrier developed for drug delivery across the BBB; 3D face analysis could screen for sleep apnea; Long noncoding RNA has sex-specific role in depression; Noncoding TET2 variants affect neurodegeneration risk.
Read More
Keith Ligon, chief of neuropathology, Brigham and Women's Hospital

For gliomas, hypermutated does not mean sensitive to checkpoint blockade

April 17, 2020
By Anette Breindl
The largest study to date on hypermutated gliomas has delivered new insights into their origin, as well as their response to several different treatments. Specifically, even though they are hypermutated, such tumors are unlikely to respond to PD-1 blockers.
Read More

BioWorld MedTech’s Neurology Extra for April 17, 2020

April 17, 2020
By Andrea Applegate and Anette Breindl
Keeping you up to date on recent developments in neurology, including: Gene variant may protect against Alzheimer's; Miniature microscope used to study neural circuit activity in nonhuman primate model; Dopamine has epigenetic role in addiction; Depression’s structural problem.
Read More
Brain

Researchers develop long-lasting, flexible neural interface

April 13, 2020
By Stacy Lawrence
The human body constantly assaults medical devices that are implanted within it. The traditional solution to that has been to encase them in titanium. But that’s not the best option in the brain, where it remains difficult to place a high number of electrodes without damaging the brain, while protecting the device from long-term damage.
Read More
3-19-Sandia-MEG.png

Sandia Labs develops a wearable brain imager

April 13, 2020
By Annette Boyle
Albuquerque, N.M.-based Sandia Labs received a $6 million grant from the NIH to build a prototype for a wearable brain scanner. The noninvasive functional brain imaging system will use optically pumped magnetometers (OPMs) to conduct more accurate magnetoencephalography (MEG), while improving accuracy, increasing comfort, reducing imaging costs, and enabling use in more patients.
Read More

BioWorld MedTech’s Neurology Extra for April 10, 2020

April 10, 2020
By Andrea Applegate
Keeping you up to date on recent developments in neurology, including: NIH trial screening data links high amyloid levels with early stage Alzheimer's; Optical imaging technology developed for the brain; Using TMS to treat adults with autism and depression.
Read More
4-8-Silvercloud.png

Silvercloud Health raises $16M in series B

April 8, 2020
By Meg Bryant
Digital mental health startup Silvercloud Health Inc. has scooped up $16 million in a series B round led by Memorialcare Innovation Fund. The Boston-based company plans to use the funds to grow program offerings in North America, enhance its global portfolio and conduct new research and clinical trials. LRV Ventures, OSF Ventures and Unitypoint Health Ventures also participated in the round, along with existing investors Act Venture Capital and B Capital Group. With this latest round, Silvercloud has raised a total of $30 million.
Read More
Magventure-TMS.png

High-dose TMS offers depression remission in small Stanford study

April 7, 2020
By Stacy Lawrence
To better tap into the potential of transcranial magnetic stimulation (TMS), Stanford University researchers developed a high-dose, precision-targeted protocol known as Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT).
Read More

BioWorld MedTech’s Neurology Extra for April 3, 2020

April 3, 2020
By Andrea Applegate and Anette Breindl
Keeping you up to date on recent developments in neurology, including: Engineers 3D print brain implants; Minimal phenotyping gives minimal insights into MDD genetics; Optogenetic plaque model traces neurodegeneration in AD; Once repulsive, always repulsive.
Read More
Previous 1 2 … 71 72 73 74 75 76 77 78 79 … 83 84 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 16, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing